Skip to main content
SpringerLink
Log in

Colorectal Cancer: Postoperative Adjuvant Therapy and Surveillance

  • Chapter
  • First Online:
The ASCRS Textbook of Colon and Rectal Surgery

  • 3946 Accesses

Abstract

Recurrence following surgery for colorectal cancer with curative intent is not uncommon. Adjuvant systemic chemotherapy for stage III colon cancer, for stage II/III rectal cancer, and possibly for high-risk stage II colon cancer reduces the risk of recurrence and improves survival. Radiotherapy is more effective and less toxic if given prior to proctectomy rather than postoperatively. Although surveillance testing following curative resection of colorectal cancer has benefit in select patients, the optimal frequency and modality of testing remain unclear. There is a growing consensus regarding the lack of benefit from intensive surveillance regimens. The ability to identify early recurrence provides patients little benefit in terms of cancer-specific survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.

    PubMed  Google Scholar 

  2. Vogel JD, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of colon cancer. Dis Colon Rectum. 2017;60(10):999–1017.

    PubMed  Google Scholar 

  3. Andre T, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.

    CAS  PubMed  Google Scholar 

  4. Jemal A, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106–30.

    PubMed  Google Scholar 

  5. Moertel CG, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352–8.

    CAS  PubMed  Google Scholar 

  6. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345(8955):939–44.

    Google Scholar 

  7. Haller DG, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23(34):8671–8.

    PubMed  Google Scholar 

  8. O’Connell MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15(1):246–50.

    PubMed  Google Scholar 

  9. Wolmark N, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993;11(10):1879–87.

    CAS  PubMed  Google Scholar 

  10. Andre T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.

    CAS  PubMed  Google Scholar 

  11. Kuebler JP, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198–204.

    CAS  PubMed  Google Scholar 

  12. Twelves C, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696–704.

    CAS  PubMed  Google Scholar 

  13. Haller DG, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–71.

    CAS  PubMed  Google Scholar 

  14. Zedan AH, et al. Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers. Clin Colorectal Cancer. 2014;13(2):73–80.

    PubMed  Google Scholar 

  15. Grothey A, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378(13):1177–88.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Benson AB, et al. Colon cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. 2020 5/6/2020 [cited 2020 5/10/2020]; Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.

  17. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol. 1999;17(5):1356–63.

    Google Scholar 

  18. Gill S, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797–806.

    CAS  PubMed  Google Scholar 

  19. Quasar Collaborative, G, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–9.

    Google Scholar 

  20. Benson AB 3rd, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–19.

    PubMed  Google Scholar 

  21. Labianca R, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi64–72.

    CAS  PubMed  Google Scholar 

  22. Gryfe R, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342(2):69–77.

    CAS  PubMed  Google Scholar 

  23. Sargent DJ, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Gavin PG, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18(23):6531–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Benson AB 3rd, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(3):370–98.

    CAS  Google Scholar 

  26. Martenson JA Jr, et al. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol. 2004;22(16):3277–83.

    CAS  PubMed  Google Scholar 

  27. Sebastian NT, et al. Surgery with and without adjuvant radiotherapy are associated with similar survival in T4 colon cancer. Color Dis. 2020;22:779.

    CAS  Google Scholar 

  28. Zhou Z, Nimeiri HS, Benson AB 3rd. Preoperative chemotherapy for locally advanced resectable colon cancer - a new treatment paradigm in colon cancer? Ann Transl Med. 2013;1(2):11.

    PubMed  PubMed Central  Google Scholar 

  29. Dehal A, et al. Neoadjuvant chemotherapy improves survival in patients with clinical T4b colon cancer. J Gastrointest Surg. 2018;22(2):242–9.

    PubMed  Google Scholar 

  30. Swedish Rectal Cancer, T, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336(14):980–7.

    Google Scholar 

  31. Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.

    CAS  PubMed  Google Scholar 

  32. Peeters KC, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246(5):693–701.

    PubMed  Google Scholar 

  33. Benson AB, et al. Rectal cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. 2020 5/6/2020 [cited 2020 5/10/2020]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.

  34. Hong YS, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014;15(11):1245–53.

    CAS  PubMed  Google Scholar 

  35. Rodel C, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13(7):679–87.

    PubMed  Google Scholar 

  36. Breugom AJ, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(2):200–7.

    CAS  PubMed  Google Scholar 

  37. Biagi JJ, et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011;305(22):2335–42.

    CAS  PubMed  Google Scholar 

  38. Fernandez-Martos C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†. Ann Oncol. 2015;26(8):1722–8.

    Google Scholar 

  39. Nogue M, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011;16(5):614–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Al-Sukhni E, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2012;19(7):2212–23.

    PubMed  Google Scholar 

  41. Fisher B, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988;80(1):21–9.

    CAS  PubMed  Google Scholar 

  42. Krook JE, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324(11):709–15.

    CAS  PubMed  Google Scholar 

  43. Mellgren A, et al. Is local excision adequate therapy for early rectal cancer? Dis Colon Rectum. 2000;43(8):1064–71. discussion 1071-4

    CAS  PubMed  Google Scholar 

  44. Endreseth BH, et al. Transanal excision vs. major surgery for T1 rectal cancer. Dis Colon Rectum. 2005;48(7):1380–8.

    PubMed  Google Scholar 

  45. Nash GM, et al. Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum. 2009;52(4):577–82.

    PubMed  Google Scholar 

  46. Bentrem DJ, et al. T1 adenocarcinoma of the rectum: transanal excision or radical surgery? Ann Surg. 2005;242(4):472–7. discussion 477-9

    PubMed  PubMed Central  Google Scholar 

  47. Nascimbeni R, et al. Long-term survival after local excision for T1 carcinoma of the rectum. Dis Colon Rectum. 2004;47(11):1773–9.

    PubMed  Google Scholar 

  48. Borschitz T, Heintz A, Junginger T. The influence of histopathologic criteria on the long-term prognosis of locally excised pT1 rectal carcinomas: results of local excision (transanal endoscopic microsurgery) and immediate reoperation. Dis Colon Rectum. 2006;49(10):1492–506. discussion 1500-5

    PubMed  Google Scholar 

  49. Junginger T, et al. Long-term oncologic outcome after transanal endoscopic microsurgery for rectal carcinoma. Dis Colon Rectum. 2016;59(1):8–15.

    PubMed  Google Scholar 

  50. Garcia-Aguilar J, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015;16(15):1537–46.

    PubMed  PubMed Central  Google Scholar 

  51. de Gramont A, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13(12):1225–33.

    PubMed  Google Scholar 

  52. Alberts SR, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307(13):1383–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Taieb J, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(8):862–73.

    CAS  PubMed  Google Scholar 

  54. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Ionov Y, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363(6429):558–61.

    CAS  PubMed  Google Scholar 

  56. Gray RG, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29(35):4611–9.

    PubMed  Google Scholar 

  57. Venook AP, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013;31(14):1775–81.

    PubMed  PubMed Central  Google Scholar 

  58. Yamanaka T, et al. 12-gene recurrence score assay stratifies the recurrence risk in stage II/III colon cancer with surgery alone: the SUNRISE study. J Clin Oncol. 2016;34(24):2906–13.

    CAS  PubMed  Google Scholar 

  59. Yothers G, et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol. 2013;31(36):4512–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. DeSantis CE, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.

    PubMed  Google Scholar 

  61. Buie WD, Attard JA. Follow-up recommendations for colon cancer. Clin Colon Rectal Surg. 2005;18(3):232–43.

    PubMed  PubMed Central  Google Scholar 

  62. Grossmann EM, et al. Follow-up of colorectal cancer patients after resection with curative intent-the GILDA trial. Surg Oncol. 2004;13(2–3):119–24.

    PubMed  Google Scholar 

  63. Vernava AM 3rd, et al. Current follow-up strategies after resection of colon cancer. Results of a survey of members of the American Society of Colon and Rectal Surgeons. Dis Colon Rectum. 1994;37(6):573–83.

    PubMed  Google Scholar 

  64. Fong Y, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18. discussion 318-21

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Kobayashi H, et al. Characteristics of recurrence after curative resection for T1 colorectal cancer: Japanese multicenter study. J Gastroenterol. 2011;46(2):203–11.

    PubMed  Google Scholar 

  66. Tsikitis VL, et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol. 2009;27(22):3671–6.

    PubMed  PubMed Central  Google Scholar 

  67. Ohlsson B, et al. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum. 1995;38(6):619–26.

    CAS  PubMed  Google Scholar 

  68. Makela JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Arch Surg. 1995;130(10):1062–7.

    CAS  PubMed  Google Scholar 

  69. Kjeldsen BJ, et al. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg. 1997;84(5):666–9.

    CAS  PubMed  Google Scholar 

  70. Schoemaker D, et al. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology. 1998;114(1):7–14.

    CAS  PubMed  Google Scholar 

  71. Rodriguez-Moranta F, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2006;24(3):386–93.

    PubMed  Google Scholar 

  72. Pietra N, et al. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum. 1998;41(9):1127–33.

    CAS  PubMed  Google Scholar 

  73. Secco GB, et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol. 2002;28(4):418–23.

    PubMed  Google Scholar 

  74. Primrose JN, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014;311(3):263–70.

    CAS  PubMed  Google Scholar 

  75. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2019;9:CD002200.

    PubMed  Google Scholar 

  76. Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50(11):1783–99.

    PubMed  Google Scholar 

  77. Pita-Fernandez S, et al. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol. 2015;26(4):644–56.

    CAS  PubMed  Google Scholar 

  78. Lepage C, et al. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: the FFCD PRODIGE 13 randomised phase III trial. Dig Liver Dis. 2015;47(7):529–31.

    PubMed  Google Scholar 

  79. Verberne CJ, et al. Intensified follow-up in colorectal cancer patients using frequent Carcino-Embryonic Antigen (CEA) measurements and CEA-triggered imaging: results of the randomized “CEAwatch” trial. Eur J Surg Oncol. 2015;41(9):1188–96.

    CAS  PubMed  Google Scholar 

  80. Verberne CJ, et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. Br J Surg. 2017;104(8):1069–77.

    CAS  PubMed  Google Scholar 

  81. Rosati G, et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. Ann Oncol. 2016;27(2):274–80.

    CAS  PubMed  Google Scholar 

  82. Wille-Jorgensen P, et al. Effect of more vs less frequent follow-up testing on overall and colorectal cancer-specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA. 2018;319(20):2095–103.

    PubMed  PubMed Central  Google Scholar 

  83. Snyder RA, et al. Association between intensity of posttreatment surveillance testing and detection of recurrence in patients with colorectal cancer. JAMA. 2018;319(20):2104–15.

    PubMed  PubMed Central  Google Scholar 

  84. Grossmann I, et al. Results of a national survey among Dutch surgeons treating patients with colorectal carcinoma. Current opinion about follow-up, treatment of metastasis, and reasons to revise follow-up practice. Color Dis. 2007;9(9):787–92.

    CAS  Google Scholar 

  85. van Steenbergen LN, et al. Large variation between hospitals in follow-up for colorectal cancer in southern Netherlands. Int J Color Dis. 2013;28(9):1257–65.

    Google Scholar 

  86. Soreide K, et al. Adherence to national guidelines for surveillance after curative resection of nonmetastatic colon and rectum cancer: a survey among Norwegian gastrointestinal surgeons. Color Dis. 2012;14(3):320–4.

    CAS  Google Scholar 

  87. Wattchow DA, et al. General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. Br J Cancer. 2006;94(8):1116–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Augestad KM, et al. Cost-effectiveness and quality of life in surgeon versus general practitioner-organised colon cancer surveillance: a randomised controlled trial. BMJ Open. 2013;3(4):e002391.

    PubMed  PubMed Central  Google Scholar 

  89. Haggstrom DA, et al. Follow-up care delivery among colorectal cancer survivors most often seen by primary and subspecialty care physicians. J Gen Intern Med. 2009;24(Suppl 2):S472–9.

    PubMed  Google Scholar 

  90. Durani U, et al. Use of imaging during staging and surveillance of localized colon cancer in a large insured population. J Natl Compr Cancer Netw. 2019;17(11):1355–61.

    Google Scholar 

  91. Cooper GS, Kou TD, Reynolds HL Jr. Receipt of guideline-recommended follow-up in older colorectal cancer survivors: a population-based analysis. Cancer. 2008;113(8):2029–37.

    PubMed  Google Scholar 

  92. Giordano P, et al. Strategies of follow-up for colorectal cancer: a survey of the American Society of Colon and Rectal Surgeons. Tech Coloproctol. 2006;10(3):199–207.

    CAS  PubMed  Google Scholar 

  93. Sargent D, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872–7.

    PubMed  PubMed Central  Google Scholar 

  94. Seo SI, et al. Comparison of recurrence patterns between </=5 years and >5 years after curative operations in colorectal cancer patients. J Surg Oncol. 2013;108(1):9–13.

    PubMed  Google Scholar 

  95. Fora A, et al. Intensive radiographic and biomarker surveillance in stage II and III colorectal cancer. Oncology. 2012;82(1):41–7.

    CAS  PubMed  Google Scholar 

  96. Steele SR, et al. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum. 2015;58(8):713–25.

    PubMed  Google Scholar 

  97. Juul T, et al. International validation of the low anterior resection syndrome score. Ann Surg. 2014;259(4):728–34.

    PubMed  Google Scholar 

  98. Peeters KC, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients – a Dutch colorectal cancer group study. J Clin Oncol. 2005;23(25):6199–206.

    CAS  PubMed  Google Scholar 

  99. Meyerhardt JA, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007;298(7):754–64.

    CAS  PubMed  Google Scholar 

  100. McCullough ML, et al. Association between red and processed meat intake and mortality among colorectal cancer survivors. J Clin Oncol. 2013;31(22):2773–82.

    PubMed  PubMed Central  Google Scholar 

  101. Meyerhardt JA, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006;24(22):3535–41.

    PubMed  Google Scholar 

  102. Irvine T, Scott M, Clark CI. A small rise in CEA is sensitive for recurrence after surgery for colorectal cancer. Color Dis. 2007;9(6):527–31.

    CAS  Google Scholar 

  103. Verberne CJ, et al. Detection of recurrences during follow-up after liver surgery for colorectal metastases: both carcinoembryonic antigen (CEA) and imaging are important. Ann Surg Oncol. 2013;20(2):457–63.

    PubMed  Google Scholar 

  104. Goslin R, et al. Correlation of Plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer. Am J Med. 1981;71(2):246–53.

    CAS  PubMed  Google Scholar 

  105. Moertel CG, et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270(8):943–7.

    CAS  PubMed  Google Scholar 

  106. Arriola E, et al. Imaging techniques contribute to increased surgical rescue of relapse in the follow-up of colorectal cancer. Dis Colon Rectum. 2006;49(4):478–84.

    PubMed  Google Scholar 

  107. Renehan AG, et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002;324(7341):813.

    PubMed  PubMed Central  Google Scholar 

  108. Patel K, et al. The lack of evidence for PET or PET/CT surveillance of patients with treated lymphoma, colorectal cancer, and head and neck cancer: a systematic review. J Nucl Med. 2013;54(9):1518–27.

    PubMed  Google Scholar 

  109. Cone MM, et al. Timing of colonoscopy after resection for colorectal cancer: are we looking too soon? Dis Colon Rectum. 2013;56(11):1233–6.

    CAS  PubMed  Google Scholar 

  110. Ohlsson B, Palsson B. Follow-up after colorectal cancer surgery. Acta Oncol. 2003;42(8):816–26.

    PubMed  Google Scholar 

  111. Rex DK, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2006;130(6):1865–71.

    PubMed  Google Scholar 

  112. Cali RL, et al. Cumulative incidence of metachronous colorectal cancer. Dis Colon Rectum. 1993;36(4):388–93.

    CAS  PubMed  Google Scholar 

  113. Wang T, et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointest Endosc. 2009;69(3 Pt 2):609–15.

    PubMed  Google Scholar 

  114. Lan YT, et al. Metachronous colorectal cancer: necessity of post-operative colonoscopic surveillance. Int J Color Dis. 2005;20(2):121–5.

    Google Scholar 

  115. Green RJ, et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med. 2002;136(4):261–9.

    CAS  PubMed  Google Scholar 

  116. Mulder SA, et al. The incidence and risk factors of metachronous colorectal cancer: an indication for follow-up. Dis Colon Rectum. 2012;55(5):522–31.

    PubMed  Google Scholar 

  117. Bouvier AM, et al. The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up. Eur J Cancer. 2008;44(4):522–7.

    PubMed  Google Scholar 

  118. Battersby NJ, et al. Metachronous colorectal cancer: a competing risks analysis with consideration for a stratified approach to surveillance colonoscopy. J Surg Oncol. 2014;109(5):445–50.

    PubMed  Google Scholar 

  119. Day LW, Walter LC, Velayos F. Colorectal cancer screening and surveillance in the elderly patient. Am J Gastroenterol. 2011;106(7):1197–206; quiz 1207.

    PubMed  Google Scholar 

  120. Tran AH, Man Ngor EW, Wu BU. Surveillance colonoscopy in elderly patients: a retrospective cohort study. JAMA Intern Med. 2014;174(10):1675–82.

    PubMed  Google Scholar 

  121. You YN, et al. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg. 2007;245(5):726–33.

    PubMed  PubMed Central  Google Scholar 

  122. Paty PB, et al. Long-term results of local excision for rectal cancer. Ann Surg. 2002;236(4):522–9. discussion 529-30

    PubMed  PubMed Central  Google Scholar 

  123. Lohnert MS, Doniec JM, Henne-Bruns D. Effectiveness of endoluminal sonography in the identification of occult local rectal cancer recurrences. Dis Colon Rectum. 2000;43(4):483–91.

    CAS  PubMed  Google Scholar 

  124. de Anda EH, et al. Endorectal ultrasound in the follow-up of rectal cancer patients treated by local excision or radical surgery. Dis Colon Rectum. 2004;47(6):818–24.

    PubMed  Google Scholar 

  125. Ramirez JM, et al. Endoluminal ultrasonography in the follow-up of patients with rectal cancer. Br J Surg. 1994;81(5):692–4.

    CAS  PubMed  Google Scholar 

  126. Morken JJ, et al. Endorectal ultrasound-directed biopsy: a useful technique to detect local recurrence of rectal cancer. Int J Color Dis. 2006;21(3):258–64.

    Google Scholar 

  127. Gleeson FC, et al. Local recurrence detection following transanal excision facilitated by EUS-FNA. Hepato-Gastroenterology. 2012;59(116):1102–7.

    PubMed  Google Scholar 

  128. Maleki Z, et al. Endorectal ultrasound-guided fine-needle aspiration: a useful diagnostic tool for perirectal and intraluminal lesions. Acta Cytol. 2013;57(1):9–18.

    PubMed  Google Scholar 

  129. Lambregts DM, et al. Value of MRI and diffusion-weighted MRI for the diagnosis of locally recurrent rectal cancer. Eur Radiol. 2011;21(6):1250–8.

    PubMed  PubMed Central  Google Scholar 

  130. Titu LV, et al. Routine follow-up by magnetic resonance imaging does not improve detection of resectable local recurrences from colorectal cancer. Ann Surg. 2006;243(3):348–52.

    PubMed  PubMed Central  Google Scholar 

  131. Kwakye G, et al. Locally excised T1 rectal cancers: need for specialized surveillance protocols. Dis Colon Rectum. 2019;62(9):1055–62.

    PubMed  Google Scholar 

  132. Papagrigoriadis S, Heyman B. Patients’ views on follow up of colorectal cancer: implications for risk communication and decision making. Postgrad Med J. 2003;79(933):403–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  133. Kjeldsen BJ, et al. Influence of follow-up on health-related quality of life after radical surgery for colorectal cancer. Scand J Gastroenterol. 1999;34(5):509–15.

    CAS  PubMed  Google Scholar 

  134. Stiggelbout AM, et al. Follow-up of colorectal cancer patients: quality of life and attitudes towards follow-up. Br J Cancer. 1997;75(6):914–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  135. Dinan MA, et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA. 2010;303(16):1625–31.

    CAS  PubMed  Google Scholar 

  136. Audisio RA, et al. Follow-up in colorectal cancer patients: a cost-benefit analysis. Ann Surg Oncol. 1996;3(4):349–57.

    CAS  PubMed  Google Scholar 

  137. Renehan AG, O’Dwyer ST, Whynes DK. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. BMJ. 2004;328(7431):81.

    PubMed  PubMed Central  Google Scholar 

  138. Wanis KN, et al. Health and economic impact of intensive surveillance for distant recurrence after curative treatment of colon cancer: a mathematical modeling study. Dis Colon Rectum. 2019;62(7):872–81.

    PubMed  Google Scholar 

  139. Liu SL, Cheung WY. Role of surveillance imaging and endoscopy in colorectal cancer follow-up: quality over quantity? World J Gastroenterol. 2019;25(1):59–68.

    PubMed  PubMed Central  Google Scholar 

  140. Glimelius B, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi81–8.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lahey Hospital and Medical Center, Department of Colon and Rectal Surgery, Burlington, MA, USA

    David A. Kleiman

  2. Mayo Clinic, Department of Surgery, Rochester, MN, USA

    David W. Larson

Authors
  1. David A. Kleiman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David W. Larson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Kleiman .

Editor information

Editors and Affiliations

  1. Department of Colorectal Surgery, Cleveland Clinic, Cleveland, OH, USA

    Scott R. Steele

  2. Department of Colorectal Surgery, Cleveland Clinic, Cleveland, OH, USA

    Tracy L. Hull

  3. University of Chicago Medical Center, Chicago, IL, USA

    Neil Hyman

  4. Department of Surgery, University of Massachusetts Medical School, Worcester, MA, USA

    Justin A. Maykel

  5. Division of Gastrointestinal Surgery, University of Florida, Gainesville, FL, USA

    Thomas E. Read

  6. Department of Colon and Rectal Surgery, Ochsner Clinic, New Orleans, LA, USA

    Charles B. Whitlow

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kleiman, D.A., Larson, D.W. (2022). Colorectal Cancer: Postoperative Adjuvant Therapy and Surveillance. In: Steele, S.R., Hull, T.L., Hyman, N., Maykel, J.A., Read, T.E., Whitlow, C.B. (eds) The ASCRS Textbook of Colon and Rectal Surgery. Springer, Cham. https://doi.org/10.1007/978-3-030-66049-9_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-66049-9_30

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-66048-2

  • Online ISBN: 978-3-030-66049-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation